Around one in every 10 people will suffer from depression. Brain regions that control mood are often disrupted in depression. Antidepressant drugs or behavioral therapy can offer some relief. By understanding the brain better, our ability to treat depression should also get a boost.
Watch the video to learn about the neural circuits affected in depression, and the molecular and cellular changes that might hold the key to treating it. Created by the editors at Nature Neuroscience: http://www.nature.com/neuro/index.html
Nature has full responsibility for all editorial content, including Nature Video content. This content is editorially independent of sponsors.
Sign up for the Nature Briefing: An essential round-up of science news, opinion and analysis, free in your inbox every weekday. https://go.nature.com/371OcVF
Mood naturally fluctuates, and everyone experiences highs and lows in their lives.
But in some cases, changes in mood can become long-lasting, debilitating,
and can impair someone's ability to hold down a job or sustain meaningful relationships.
It's estimated that around 10% of people will at some point in their lives suffer from depression,
a mood disorder characterised by several symptoms.
Feeling sad,
distressed,
unmotivated,
excessively tired,
and losing interest in once pleasurable activities, known as anhedonia.
Many people with depression also suffer from anxiety.
Neuroimaging studies reveal that many brain circuits that normally regulate mood
are dysregulated in depression.
Located deep within the brain,
the amygdala processes highly salient stimuli such as rewards and potential threats.
In depression, the amygdala is overactive and responds excessively to negative events.
In turn, the amygdala connects to a set of brain regions
that hone the physiological and behavioural response to emotional stimuli.
These areas include the medial prefrontal cortex,
the nucleus accumbens,
the hippocampus,
and the insula.
The hippocampus is involved in memory formation,
and along with the prefrontal cortex,
is particularly vulnerable to the effects of stress.
Depressed people are more susceptible to stress,
which can cause physical changes in the brain,
including atrophy of the hippocampus.
This, and other changes in depressed people,
may cause inappropriate responses to emotional events.
The medial prefrontal cortex is involved in regulating how strongly we react to emotional stimuli.
Treatments such as antidepressant drugs,
cognitive behavioural therapy,
and electroconvulsive therapy
affect the structure and function of these and other brain regions.
Animal models such as mice are critical in helping us understand
the cellular and molecular changes underlying depression
and develop better treatments.
Although it's impossible to know if a mouse is depressed,
mice subjected to chronic stress show some symptoms similar to depressed humans,
such as anxiety-like behaviour,
less social interaction,
and a lack of interest in normally pleasurable activities.
While not all human depression is triggered by stress,
these models may still shed light on the biology of depression,
and they're the closest scientists can get while studying mice.
As with humans, chronic stress in mice can lead to atrophy of the hippocampus and prefrontal cortex.
Mouse studies have also shown altered neuronal plasticity in various brain regions,
including the hippocampus, prefrontal cortex, amygdala, and nucleus accumbens.
In a healthy hippocampus, experiences can lead to changes in the connections between neurons,
resulting in learning.
These changes are referred to as plasticity.
Chronic stress can reduce this plasticity.
Healthy brains also continue to produce new neurons in one part of the hippocampus.
These new neurons slowly mature and integrate into the circuitry,
where they have a strong effect on hippocampal activity and behaviour.
These new neurons are also affected by stress.
They're reduced in number in stressed brains.
These effects may result from reduced levels of neurotrophins,
proteins that increase neuronal growth and plasticity.
Reduced plasticity may stop the hippocampus from being able to properly regulate the stress response,
which may lead to a vicious cycle where stress perpetuates more stress.
The hippocampus is particularly affected,
but there can be reductions in plasticity elsewhere in the brain,
and together these changes could contribute to other symptoms of depression, like anhedonia.
Whether these cellular changes seen in mice are involved in human depression remains unclear.
Most antidepressants available today rapidly increase the amount of the neurotransmitters
serotonin and or norepinephrine in the synapse.
However, improvements in symptoms in patients and mice
usually don't occur until weeks after starting the treatment.
While the reasons for this delay aren't fully understood,
prolonged treatment with antidepressants can, over time,
act to reverse some of the changes induced by chronic stress,
increasing neurotrophin expression and rebooting hippocampal plasticity.
Non-chemical treatments for depression, including electroconvulsive shock,
also promote hippocampal plasticity in mice.
Antidepressant treatment can also reverse stress-induced changes in other areas of the brain,
including the prefrontal cortex and reward circuitry.
Different treatments may target different regions to improve symptoms.
Recently, the drug ketamine was found to have rapid antidepressant effects in patients with depression
as well as in rodent models, with effects lasting for days.
The mechanism behind this is an area of active research.
Ketamine blocks a type of synaptic transmission,
leading to activation of a number of signalling pathways
and increasing neurotrophin expression.
These molecular changes result in increased plasticity in the prefrontal cortex and hippocampus
and likely contribute to ketamine's behavioural effects.
By studying the changes in the brain caused by chronic stress
and how antidepressants like ketamine work to reverse them,
researchers may find new targets for treatment,
or new drugs that could act more quickly, more specifically,
or more effectively than currently available treatments.